He W, Chang J, Zhang J
Second Affiliated Hospital, Xi'an Medical University.
Zhonghua Fu Chan Ke Za Zhi. 1995 Mar;30(3):161-3.
Hyaluronate contents were determined by radioimmunoassay in 91 samples of serum, 88 samples of urine and 32 samples of ovarian tumor tissue from patients with benign and malignant tumors and from healthy subjects. The mean serum hyaluronate level in patients with malignant ovarian tumors (mean, 155.99 micrograms/L, range, 20 to 680 micrograms/L) was significantly higher than that in patients with benign ovarian tumors (mean, 84.2 micrograms/L; range, 20 to 188 micrograms/L) and that in healthy subjects (mean, 57 micrograms/L; range, 2 to 110 micrograms/L). The mean urine hyaluronate level in the malignant group (mean, 307.83 micrograms/L; range 50 to 750 micrograms/L) also was significantly higher than that in the normal control group (mean, 146 micrograms/L; range, 40 to 242 micrograms/L). The results suggest that serum and urine hyaluronate determination in the detection of malignant ovarian tumors is of clinical value.
采用放射免疫分析法测定了91份血清样本、88份尿液样本以及32份来自患有良性和恶性肿瘤的患者及健康受试者的卵巢肿瘤组织样本中的透明质酸盐含量。恶性卵巢肿瘤患者的血清透明质酸盐平均水平（均值为155.99微克/升，范围为20至680微克/升）显著高于良性卵巢肿瘤患者（均值为84.2微克/升；范围为20至188微克/升）以及健康受试者（均值为57微克/升；范围为2至110微克/升）。恶性组的尿液透明质酸盐平均水平（均值为307.83微克/升；范围为50至750微克/升）也显著高于正常对照组（均值为146微克/升；范围为40至242微克/升）。结果表明，测定血清和尿液中的透明质酸盐对检测恶性卵巢肿瘤具有临床价值。
